Angiostatin and endostatin: endogenous inhibitors of tumor growth.
Considerable progress has been made in the understanding of the molecular structure and mechanistic aspects of Angiostatin and Endostatin, endogenous angiogenesis inhibitors that have been shown to regress tumors in murine models. The growing body of literature surrounding these molecules and on the efficacy of these proteins is in part due to the ability to generate these proteins in recombinant systems as well characterized molecules. Recombinant human Angiostatin and Endostatin are in Phase I trials, following the manufacture of clinical grade material at large scale. This review highlights the recent advances made on understanding the structure and function of Angiostatin and Endostatin.
Sim
B K
BK
EntreMed Inc, Rockville, MD 20850, USA.
MacDonald
N J
NJ
Gubish
E R
ER
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use* / Q000633:toxicity; D043168:Angiostatins; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D002986:Clinical Trials as Topic; D003094:Collagen / Q000502:physiology* / Q000627:therapeutic use* / Q000633:toxicity; D043169:Endostatins; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology; D010446:Peptide Fragments / Q000502:physiology* / Q000627:therapeutic use* / Q000633:toxicity; D010958:Plasminogen / Q000502:physiology* / Q000627:therapeutic use* / Q000633:toxicity; D011994:Recombinant Proteins / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D043169:Endostatins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D043168:Angiostatins; D010958:Plasminogen; D003094:Collagen